Real world evidence (RWE) refers to data collected outside the context of traditional clinical trials, such as observational studies, registries, and electronic health records. RWE can provide valuable insights into the safety, effectiveness, and real-world use of drugs, and has the potential to transform drug development.
Some of the opportunities of real world evidence in drug development include:
1. Improved patient recruitment: RWE can help identify patient populations that are typically underrepresented in clinical trials, such as elderly patients, patients with multiple comorbidities, and those with rare diseases. This can help improve patient recruitment and enable more representative clinical trials.
2. Enhance clinical trial design: RWE can help inform the design of clinical trials, for example, by identifying appropriate endpoints, understanding patient demographics, and identifying potential confounding factors that need to be accounted for.
Identify safety concerns: RWE can help identify safety concerns that may not have been detected in clinical trials, especially those related to long-term use or rare adverse events. This can help improve post-marketing surveillance and ensure that drugs are used safely in the real world.
3. Better understanding of effectiveness: RWE can provide insights into the effectiveness of drugs in the real world, including how drugs are used in combination with other treatments, and how patient outcomes vary across different subpopulations.
4. Accelerate drug development: By leveraging RWE, drug development timelines can be accelerated as fewer resources are required for clinical trials, making it easier to conduct larger and more complex studies. Additionally, RWE can help optimize the design of clinical trials, reducing the likelihood of failed trials and resulting in faster regulatory approvals.
In summary, real world evidence has the potential to improve drug development in a number of ways, including patient recruitment, clinical trial design, safety monitoring, and accelerating drug development timelines. By leveraging RWE, drug developers can gain a better understanding of how drugs work in the real world, which can ultimately improve patient outcomes.
Share this story...
Real World Evidence (RWE) 101 – Ethical Imperatives (CIOMS 2023)
RWE 101 - Ethical Imperatives (CIOMS 2023) Informed decision making with patients typically relies on evidence from clinical trials that describe the likely benefits and toxicities. However, patients treated [...]
Real World Evidence (RWE) 101 – Ethical Imperatives
RWE 101 - Ethical Imperatives Real-world evidence (RWE) refers to the clinical evidence regarding the usage and potential benefits or risks of a product derived from analysis of real-world [...]
Real World Evidence (RWE) 101 – The Importance of Intent
RWE 101 - The Importance of Intent Real-world evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a product derived from the analysis [...]
Real World Evidence (RWE) 101 – Inspections
RWE 101 - Inspections Real-World Evidence (RWE) can include data from sources such as electronic health records (EHRs), insurance claims and billing activities, patient registries, patient-generated data, and data [...]
Real World Evidence (RWE) 101 – Audits
RWE 101 - Audits A quality assurance auditor in the context of a real-world evidence (RWE) study has several responsibilities, key among them ensuring that all facets of the [...]
Real World Evidence (RWE) 101 – Compliance Maps
RWE 101 - Compliance Maps In the context of multi-country Real-World Evidence (RWE) studies, "Regulatory Compliance Maps" are essentially a detailed representation of the diverse regulatory requirements specific to [...]







